Dr Reddy's Resolves Legacy Issues At Duvvada After FDA Clears Plant
Executive Summary
Dr Reddy’s has been given the all-clear for its Indian formulations manufacturing facility in Duvvada, Visakhapatnam, after the FDA issued an EIR closing out an inspection at the plant that has suffered longstanding quality issues.
You may also be interested in...
Manufacturing Round-Up: Sterling Completes Expansion As Xellia Teams With Civica Rx
Sterling Pharma Solutions completes an expansion of its UK pilot plant facility, Aphena invests, Dr Reddy’s and Asymchem get nods from the FDA, Ampersand Capital Partners acquires Germany’s Vibalogics, and Xellia strikes a deal with Civica Rx.
Dr Reddy’s Acquires Portfolio Of 42 ANDAs To Spur Growth In US
Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.
Manufacturing Roundup – 1 April 2019
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.